MyD88 Antibody
- Known as:
- MyD88 Antibody
- Catalog number:
- 3244R-100
- Product Quantity:
- 100
- Category:
- -
- Supplier:
- Biovis
- Gene target:
- MyD88 Antibody
Related genes to: MyD88 Antibody
- Gene:
- MYD88 NIH gene
- Name:
- MYD88 innate immune signal transduction adaptor
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 3p22.2
- Locus Type:
- gene with protein product
- Date approved:
- 1997-12-23
- Date modifiied:
- 2019-04-23
Related products to: MyD88 Antibody
Related articles to: MyD88 Antibody
- To investigate the therapeutic effect of Kushen Tongguan Pill (KSTG) on benign prostatic hyperplasia (BPH) induced by castration combined with testosterone propionate in rats, and to explore its underlying mechanism associated with the Toll-like receptor 4/nuclear factor κB (TLR4/NF-κB) signaling pathway. - Source: PubMed
Publication date: 2026/09/04
Chen ShaofengWang JieFeng YuhongLi ChunxuWang FuMiao LinLi YaojunLei YangyangGeng QiangLi ZhongZhao FengSun YuanDu Lijian - Insomnia is closely associated with neuroinflammation, yet the therapeutic mechanism of electroacupuncture (EA) remains unclear. This animal study investigated whether EA attenuates hypothalamic neuroinflammation in para-chlorophenylalanine (PCPA)-induced insomnia rats by suppressing the TLR4/MyD88/NF-κB p65 pathway and M1 microglial activation, using TAK-242 (HY-11109), a selective TLR4 inhibitor, as a positive control. - Source: PubMed
Publication date: 2026/08/30
Zhang MengLiu LianTan TianHe LijuanHu BingqingLi SixianJiang MengyaDeng PengRen Qingjia - Diarrhea in suckling lambs is associated with gut microbiota dysbiosis, impaired intestinal barrier function, and enhanced inflammatory responses. However, the specific intestinal microbes and microbial metabolites linked to intestinal homeostasis in suckling lambs remain unclear. - Source: PubMed
Publication date: 2026/09/04
Li JiahaoWang ZhengliMa XiaoxueNie CunxiLiu TingtingLi YuanyuanZhang Wenju - This study aimed to investigate the neuroprotective effects of paeoniflorin in a pentylenetetrazol(PTZ)-induced zebrafish model of epilepsy. Zebrafish at four days post-fertilization with normal development were randomly divided into a control group, a model group, a positive control group(sodium valproate), and paeoniflorin treatment groups(200, 400, and 800 μmol·L~(-1)). Behavioral analysis was performed to evaluate changes in locomotor activity. Fluorescence microscopy was employed to evaluate neuronal discharge in the brain, cellular apoptosis, and the accumulation of neutrophils and macrophages. The levels of reactive oxygen species(ROS) and malondialdehyde(MDA) in the brain were measured to assess antioxidant capacity. Quantitative real-time polymerase chain reaction(RT-qPCR) was used to detect the mRNA expression levels of epilepsy-related genes(c-fos, brain-derived neurotrophic factor [BDNF], and galanin [GALN]) and inflammation-related genes(interleukin [IL]-1β, IL-6, and tumor necrosis factor-α [TNF-α]). Furthermore, the TLR4 receptor agonist lipopolysaccharide(LPS) was used for intervention. Behavioral analysis and RT-qPCR were conducted to detect the mRNA expression levels of Toll-like receptor 4(TLR4), myeloid differentiation factor 88(MyD88), nuclear factor-κB(NF-κB), and IL-1β, in order to verify the role of the related signaling pathway. The results demonstrated that, compared with the model group, paeoniflorin improved PTZ-induced epileptic behaviors, reduced the total swimming distance and velocity of zebrafish, and significantly downregulated the mRNA expression levels of epilepsy-related genes c-fos, BDNF, and GALN. Meanwhile, paeoniflorin significantly inhibited PTZ-induced abnormal neuronal discharge in the brain, suppressed cellular apoptosis, and reduced ROS levels and MDA content. In addition, paeoniflorin significantly attenuated the PTZ-induced accumulation of macrophages and neutrophils in the brain and downregulated the expression of inflammatory genes IL-1β, IL-6, and TNF-α. Further findings demonstrated that LPS intervention significantly attenuated the ameliorative effects of paeoniflorin on PTZ-induced epileptiform behaviors in zebrafish. RT-qPCR results showed that LPS treatment markedly reversed the inhibitory effects of paeoniflorin on the mRNA expression levels of TLR4, MyD88, NF-κB, and IL-1β in PTZ-induced zebrafish. In conclusion, this study indicates that paeoniflorin may exert its neuroprotective effects in a PTZ-induced zebrafish epilepsy model primarily by suppressing the activity of the TLR4/NF-κB signaling pathway, thereby reducing oxidative stress and inflammatory responses in the brain, suppressing neuronal apoptosis, and alleviating abnormal neuronal discharge. - Source: PubMed
Liu Xin-YueZheng Kang-diLiu Jia-YuZhang Teng-FeiYang Qiong-YingZhang ZhaoChen Tao - Primary effusion lymphoma (PEL) and fluid overload-associated large B-cell lymphoma (FO-LBCL) are rare B-cell neoplasms presenting as serous effusions without solid masses, distinguished primarily by human herpesvirus-8 status. We analyzed three PEL and seven FO-LBCL cases using immunohistochemistry, Epstein-Barr virus-encoded RNA in situ hybridization, immunoglobulin heavy chain (IGH), T-cell receptor beta (TRB) and T-cell receptor gamma (TRG) gene rearrangement analyses, and targeted next-generation sequencing. The median age was 72 years for PEL and 83 years for FO-LBCL. All PEL cases lacked CD20, whereas FO-LBCL tumors retained pan-B-cell markers. Aberrant T-cell antigen expression was observed in two PEL cases, both showing clonal T-cell receptor rearrangements in addition to IGH clonality. FO-LBCL harbored recurrent alterations involving CD79B, PIM1, and MYD88, suggesting partial molecular overlap with the molecular features characteristic of the MCD subtype of diffuse large B-cell lymphoma (DLBCL). Clinically, all patients with PEL died of disease, whereas FO-LBCL appeared to have a more favorable clinical course, with four patients remaining alive at the last follow-up. Despite morphologic overlap, PEL and FO-LBCL showed distinct immunophenotypic, genetic, and clinical features. These preliminary findings support further investigation of B-cell receptor/NF-κB-related signaling pathways in FO-LBCL and may contribute to improved molecular classification and future therapeutic stratification. - Source: PubMed
Publication date: 2026/09/03
Jeon TaesungKo Young-HyehSung You-NaOh HarimKim HyunsungBang SeongsikKang Ka-WonKim ChanggonKwak KunyeKim YeseulAhn Sangjeong